Search Within
Applied Filters:
Showing 1-15 of 15 results for "


" within Papers
Yvonne Rosenberg et al.
PloS one, 10(3), e0120451-e0120451 (2015-03-26)
The identification of highly potent broadly neutralizing antibodies (bnAbs) against HIV-1, and success in preventing SHIV infection following their passive administration, have increased the likelihood that immunotherapeutic strategies can be adopted to prevent and treat HIV-1 infection. However, while broad...
Muriel Viau et al.
Infection and immunity, 72(6), 3515-3523 (2004-05-25)
Some pathogens have evolved to produce proteins, called B-cell superantigens, that can interact with human immunoglobulin variable regions, independently of the combining site, and activate B lymphocytes that express the target immunoglobulins. However, the in vivo consequences of these interactions...
Ruben J Boado et al.
Biotechnology and bioengineering, 96(2), 381-391 (2006-08-29)
A murine monoclonal antibody (MAb) to the human insulin receptor (HIR) has been engineered for use as a brain drug delivery system for transport across the human blood-brain barrier (BBB). The HIRMAb was humanized by complementarity determining region (CDR) grafting...
Koreen Ramessar et al.
Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3727-3732 (2008-03-05)
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite...
S M Chamow et al.
Journal of immunology (Baltimore, Md. : 1950), 153(9), 4268-4280 (1994-11-01)
HIV infection depletes the immune system of the coordinating functions of CD4+ T cells and APCs, whereas the population of CD8+ CTLs remains largely intact: functional but undirected. We have developed a humanized bispecific immunoadhesin-antibody (BIA) that redirects these remaining...
Joschka Bauer et al.
mAbs, 12(1), 1787121-1787121 (2020-07-14)
The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) properties...
Yvonne Rosenberg et al.
PloS one, 8(3), e58724-e58724 (2013-03-28)
Passive immunotherapy using anti-HIV broadly neutralizing monoclonal antibodies (mAbs) has shown promise as an HIV treatment, reducing mother-to-child-transmission (MTCT) of simian/human immunodeficiency virus (SHIV) in non-human primates and decreasing viral rebound in patients who ceased receiving anti-viral drugs. In addition...
Richard J Zahrl et al.
Microbiology (Reading, England), 164(4), 453-463 (2018-03-14)
The yeast Pichia pastoris (syn. Komagataella spp.) is a popular cell factory for recombinant protein production. Yeasts in general provide a good starting point for cell factory engineering. They are intrinsically robust and easy to manipulate and cultivate. However, their...
Kevin C Entzminger et al.
Protein engineering, design & selection : PEDS, 28(10), 365-377 (2015-08-19)
Antibody aggregation is frequently mediated by the complementarity determining regions within the variable domains and can significantly decrease purification yields, shorten shelf-life and increase the risk of anti-drug immune responses. Aggregation-resistant antibodies could offset these risks; accordingly, we have developed...
Evangelia Vamvaka et al.
Plant biotechnology journal, 14(1), 97-108 (2015-04-08)
Protein microbicides against HIV can help to prevent infection but they are required in large, repetitive doses. This makes current fermenter-based production systems prohibitively expensive. Plants are advantageous as production platforms because they offer a safe, economical and scalable alternative...
Yvonne J Rosenberg et al.
PloS one, 11(3), e0152760-e0152760 (2016-04-01)
Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived...
Sven Mathias et al.
Biotechnology and bioengineering, 117(1), 5-16 (2019-10-22)
Although most therapeutic monoclonal antibodies (mAbs) can routinely be produced in the multigram per litre range, some mAb candidates turn out to be difficult-to-express (DTE). In addition, the class of more complex biological formats is permanently increasing and mammalian expression...
Characterization of immunological interactions at an immunoelectrode by scanning electron microscopy
Ambrosi A et al
Electroanalysis, 19, 244-252 (2007)
Melissa Pynnonen et al.
PLoS pathogens, 7(7), e1002104-e1002104 (2011-07-14)
Staphylococcus aureus nasal colonization is an important risk factor for community and nosocomial infection. Despite the importance of S. aureus to human health, molecular mechanisms and host factors influencing nasal colonization are not well understood. To identify host factors contributing...
Florian Krammer et al.
PloS one, 5(10), e13265-e13265 (2010-10-16)
Recombinant protein expression in mammalian cells has become a very important technique over the last twenty years. It is mainly used for production of complex proteins for biopharmaceutical applications. Transient recombinant protein expression is a possible strategy to produce high...
Page 1 of 1
Page 1 of 1